2496 Stock Overview
A biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Wuhan YZY Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.19 |
| 52 Week High | HK$11.76 |
| 52 Week Low | HK$5.85 |
| Beta | 0 |
| 11 Month Change | 0.49% |
| 3 Month Change | -17.14% |
| 1 Year Change | -42.69% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.31% |
Recent News & Updates
Shareholder Returns
| 2496 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -10.7% | -0.4% | -1.0% |
| 1Y | -42.7% | 2.7% | 20.3% |
Return vs Industry: 2496 underperformed the Hong Kong Biotechs industry which returned 2.7% over the past year.
Return vs Market: 2496 underperformed the Hong Kong Market which returned 20.3% over the past year.
Price Volatility
| 2496 volatility | |
|---|---|
| 2496 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2496 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2496's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 114 | Pengfei Zhou | www.yzybio.com |
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.
Wuhan YZY Biopharma Co., Ltd. Fundamentals Summary
| 2496 fundamental statistics | |
|---|---|
| Market cap | HK$1.20b |
| Earnings (TTM) | -HK$200.82m |
| Revenue (TTM) | HK$8.83m |
136.0x
P/S Ratio-6.0x
P/E RatioIs 2496 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2496 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.07m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥8.07m |
| Other Expenses | CN¥191.60m |
| Earnings | -CN¥183.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,275.35% |
| Debt/Equity Ratio | 241.0% |
How did 2496 perform over the long term?
See historical performance and comparison